淋病治療薬の世界市場レポート 2025年

淋病治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.2％で24億2,000万米ドルに成長します。予測期間の成長は、性感染症の罹患率の上昇、個別化医療への注目の高まり、抗生物質耐性パターンの増加、淋病の有病率の上昇、効果的な治療に対する需要の高まりに起因しています。主な動向としては、技術の発展、高度な診断テストの開発、新しい治療薬、併用療法、迅速な医薬品承認に対する規制当局の支援などが挙げられます。

性感染症（STI）の罹患率の上昇は、今後数年間の淋病治療薬市場の成長を牽引すると予想されます。STIは性的接触によって感染する感染症で、細菌、ウイルス、寄生虫によって引き起こされます。STIの増加は、無防備な性行為、認識や教育の欠如、性的パートナーの増加、コンドーム使用の減少、検査や治療の不十分さや遅れといった要因に起因しています。淋病治療薬は、淋菌を標的としたSTIの治療、合併症の予防、感染の減少に重要な役割を果たしています。例えば、2024年6月、オランダの政府機関である国立公衆衛生環境研究所は、SHCで診断された淋病患者が大幅に増加し、2022年の1万600人から2023年には1万3,853人に増加したと報告しました。このようなSTIの有病率の増加が、淋病治療薬市場の拡大に拍車をかけています。

淋病治療薬市場の主要企業は、迅速なポリメラーゼ連鎖反応（PCR）検査などの革新的なソリューションの開発に注力しており、医療の現場で迅速かつ正確に病原体を検出し、抗生物質耐性を分析できるようにしています。迅速PCR検査は、特定のDNAまたはRNA配列を増幅・検出する診断ツールであり、病原体や遺伝物質の迅速な同定を可能にします。例えば、2024年2月、米国の医療技術企業であるVisby Medical, Inc.は、抗菌薬耐性チェックを含む淋病検査を発表しました。この迅速診断検査は、淋病の原因菌である淋菌の存在を特定すると同時に、一部の淋菌が耐性を獲得している抗生物質であるシプロフロキサシンに対する感受性を評価します。この検査は、ポータブルで器具を必要としないPCRプラットフォームの一部であり、ポイント・オブ・ケアでの即時検査を可能にします。米国の非営利団体CARB-Xからの資金提供を受けて開発されたこの検査は、男性のクラミジア・トラコマティスやトリコモナス膣炎を含む他の性感染症の検出にも拡大する予定です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界淋病治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の淋病治療薬市場：成長率分析
• 世界の淋病治療薬市場の実績：規模と成長, 2019-2024
• 世界の淋病治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界淋病治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の淋病治療薬市場治療クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗生物質
• 併用療法
• 単剤療法
• 世界の淋病治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 筋肉内
• 世界の淋病治療薬市場：年齢層別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 成人用
• 高齢者
• 世界の淋病治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の淋病治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• ホームケア
• 世界の淋病治療薬市場抗生物質の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータラクタム
• マクロライド
• フルオロキノロン
• アミノグリコシド
• 世界の淋病治療薬市場、併用療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 二重抗生物質療法
• 3剤併用抗生物質療法
• 世界の淋病治療薬市場単剤療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単回抗生物質治療
• その他の単剤療法の選択肢

第7章 地域別・国別分析

• 世界の淋病治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の淋病治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 淋病治療薬市場：競合情勢
• 淋病治療薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Becton Dickinson and Company
• Hologic Inc.
• Aurobindo Pharma Limited
• Innoviva Inc.
• Debiopharm Group
• Achilles Vaccines S.r.l.
• Melinta Therapeutics LLC
• VenatoRx Pharmaceuticals Inc.
• Evofem Biosciences Inc.
• Recce Pharmaceuticals Ltd.
• Therapyx Inc.
• Entasis Therapeutics Inc.
• Apotex Inc.
• Alopexx Pharmaceuticals LLC
• Summit Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 淋病治療薬市場2029：新たな機会を提供する国
• 淋病治療薬市場2029：新たな機会を提供するセグメント
• 淋病治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gonorrhea therapeutics refer to treatments and medications used to manage and cure gonorrhea, a sexually transmitted infection (STI) caused by *Neisseria gonorrhoeae. These treatments primarily rely on antibiotics, often administered in combination to prevent resistance and ensure effective bacterial eradication.

The main classes of gonorrhea therapeutics include antibiotics, combination therapy, and monotherapy. Antibiotics are specifically designed to eliminate the bacteria responsible for gonorrhea, commonly including drugs such as azithromycin and ceftriaxone. These treatments are administered through oral, intravenous, and intramuscular routes and are tailored for different age groups, including pediatric, adult, and geriatric patients. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, while the primary end users comprise hospitals, clinics, and home care settings.

The gonorrhea therapeutics market research report is one of a series of new reports from The Business Research Company that provides gonorrhea therapeutics market statistics, including the gonorrhea therapeutics industry global market size, regional shares, competitors with the gonorrhea therapeutics market share, detailed gonorrhea therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the gonorrhea therapeutics industry. This gonorrhea therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gonorrhea therapeutics market size has grown strongly in recent years. It will grow from $1.88 billion in 2024 to $1.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.4%. The growth during the historic period can be credited to the rising resistance of Neisseria gonorrhoeae, the increasing prevalence of gonorrhea, the growing impact of antimicrobial resistance (AMR), heightened antibiotic resistance, and the expanding use of dual therapy treatments.

The gonorrhea therapeutics market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be credited to the rising incidence of sexually transmitted infections, a growing focus on personalized medicine, increasing antibiotic resistance patterns, a higher prevalence of gonorrhea, and the growing demand for effective treatment. Key trends include technological advancements, the development of advanced diagnostic tests, new therapeutics, combination therapies, and regulatory support for expedited drug approvals.

The rising incidence of sexually transmitted infections (STIs) is expected to drive the growth of the gonorrhea therapeutics market in the coming years. STIs are infections transmitted through sexual contact and are caused by bacteria, viruses, or parasites. The increase in STIs is attributed to factors such as unprotected sex, lack of awareness or education, a higher number of sexual partners, reduced condom use, and inadequate or delayed testing and treatment. Gonorrhea therapeutics play a crucial role in treating STIs by targeting the Neisseria gonorrhoeae bacteria, preventing complications, and reducing transmission. For example, in June 2024, the National Institute for Public Health and the Environment, a Netherlands-based government agency, reported a significant rise in gonorrhea cases diagnosed at SHCs, increasing from 10,600 in 2022 to 13,853 in 2023, reflecting a 31% year-over-year growth. This growing prevalence of STIs is fueling the expansion of the gonorrhea therapeutics market.

Leading companies in the gonorrhea therapeutics market are focused on developing innovative solutions, such as rapid polymerase chain reaction (PCR) tests, to enable quick and accurate pathogen detection and antibiotic resistance analysis at the point of care. A rapid PCR test is a diagnostic tool that amplifies and detects specific DNA or RNA sequences, allowing for fast identification of pathogens or genetic material. For instance, in February 2024, Visby Medical, Inc., a US-based medical technology company, introduced a gonorrhea test that includes an antimicrobial resistance check. This rapid diagnostic test identifies the presence of Neisseria gonorrhoeae, the bacteria responsible for gonorrhea, while also assessing its susceptibility to ciprofloxacin, an antibiotic to which some gonorrhea strains have developed resistance. The test is part of a portable, instrument-free PCR platform that allows immediate testing at the point of care. Developed with funding from the US non-profit organization CARB-X, the company plans to expand the test to detect other sexually transmitted infections, including Chlamydia trachomatis and Trichomonas vaginalis, in men.

In November 2024, the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a US-based biopharmaceutical company, partnered with the Clinton Health Access Initiative (CHAI) to enhance antimicrobial resistance (AMR) response and address gonorrhea treatment challenges. This collaboration aims to assess clinical needs and overcome market barriers for gonorrhea diagnostics, prevention, and treatment in low- and middle-income countries, with a focus on drug-resistant Neisseria gonorrhoeae to improve patient care and expand access to effective AMR solutions. CHAI, a US-based health organization, works to improve access to gonorrhea therapeutics, including diagnostics, treatments, and preventive strategies.

Major players in the gonorrhea therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, GlaxoSmithKline plc, Becton Dickinson and Company, Hologic Inc., Aurobindo Pharma Limited, Innoviva Inc., Debiopharm Group, Achilles Vaccines S.r.l., Melinta Therapeutics LLC, VenatoRx Pharmaceuticals Inc., Evofem Biosciences Inc., Recce Pharmaceuticals Ltd., Therapyx Inc., Entasis Therapeutics Inc., Apotex Inc., Alopexx Pharmaceuticals LLC, and Summit Therapeutics Inc.

North America was the largest region in the gonorrhea therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gonorrhea therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gonorrhea therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gonorrhea therapeutics market consists of revenues earned by entities by providing services such as diagnostic testing services, sexual health and counseling services, telemedicine, and online consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The gonorrhea therapeutics market also includes sales of pediatric formulations, single-dose regimens, sulfonamides, and penicillin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gonorrhea Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gonorrhea therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gonorrhea therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gonorrhea therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutic Class: Antibiotics; Combination Therapy; Monotherapy
• 2) By Route Of Administration: Oral; Intravenous; Intramuscular
• 3) By Age Group: Pediatric; Adult; Geriatric
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End User: Hospitals; Clinics; Home Care
• Subsegments:
• 1) By Antibiotics: Beta-lactams; Macrolides; Fluoroquinolones; Aminoglycosides
• 2) By Combination Therapy: Dual Antibiotic Therapy; Triple Antibiotic Therapy
• 3) By Monotherapy: Single Antibiotic Treatment; Other Monotherapy Options
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gonorrhea Therapeutics Market Characteristics

3. Gonorrhea Therapeutics Market Trends And Strategies

4. Gonorrhea Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Gonorrhea Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gonorrhea Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gonorrhea Therapeutics Market Growth Rate Analysis
• 5.4. Global Gonorrhea Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gonorrhea Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gonorrhea Therapeutics Total Addressable Market (TAM)

6. Gonorrhea Therapeutics Market Segmentation

• 6.1. Global Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Combination Therapy
• Monotherapy
• 6.2. Global Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• 6.3. Global Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatric
• Adult
• Geriatric
• 6.4. Global Gonorrhea Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Gonorrhea Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care
• 6.6. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta-lactams
• Macrolides
• Fluoroquinolones
• Aminoglycosides
• 6.7. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Combination Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dual Antibiotic Therapy
• Triple Antibiotic Therapy
• 6.8. Global Gonorrhea Therapeutics Market, Sub-Segmentation Of Monotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single Antibiotic Treatment
• Other Monotherapy Options

7. Gonorrhea Therapeutics Market Regional And Country Analysis

• 7.1. Global Gonorrhea Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gonorrhea Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gonorrhea Therapeutics Market

• 8.1. Asia-Pacific Gonorrhea Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gonorrhea Therapeutics Market

• 9.1. China Gonorrhea Therapeutics Market Overview
• 9.2. China Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gonorrhea Therapeutics Market

• 10.1. India Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gonorrhea Therapeutics Market

• 11.1. Japan Gonorrhea Therapeutics Market Overview
• 11.2. Japan Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gonorrhea Therapeutics Market

• 12.1. Australia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gonorrhea Therapeutics Market

• 13.1. Indonesia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gonorrhea Therapeutics Market

• 14.1. South Korea Gonorrhea Therapeutics Market Overview
• 14.2. South Korea Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gonorrhea Therapeutics Market

• 15.1. Western Europe Gonorrhea Therapeutics Market Overview
• 15.2. Western Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gonorrhea Therapeutics Market

• 16.1. UK Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gonorrhea Therapeutics Market

• 17.1. Germany Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gonorrhea Therapeutics Market

• 18.1. France Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gonorrhea Therapeutics Market

• 19.1. Italy Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gonorrhea Therapeutics Market

• 20.1. Spain Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gonorrhea Therapeutics Market

• 21.1. Eastern Europe Gonorrhea Therapeutics Market Overview
• 21.2. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gonorrhea Therapeutics Market

• 22.1. Russia Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gonorrhea Therapeutics Market

• 23.1. North America Gonorrhea Therapeutics Market Overview
• 23.2. North America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gonorrhea Therapeutics Market

• 24.1. USA Gonorrhea Therapeutics Market Overview
• 24.2. USA Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gonorrhea Therapeutics Market

• 25.1. Canada Gonorrhea Therapeutics Market Overview
• 25.2. Canada Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gonorrhea Therapeutics Market

• 26.1. South America Gonorrhea Therapeutics Market Overview
• 26.2. South America Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gonorrhea Therapeutics Market

• 27.1. Brazil Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gonorrhea Therapeutics Market

• 28.1. Middle East Gonorrhea Therapeutics Market Overview
• 28.2. Middle East Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gonorrhea Therapeutics Market

• 29.1. Africa Gonorrhea Therapeutics Market Overview
• 29.2. Africa Gonorrhea Therapeutics Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gonorrhea Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gonorrhea Therapeutics Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gonorrhea Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Gonorrhea Therapeutics Market Competitive Landscape
• 30.2. Gonorrhea Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Gonorrhea Therapeutics Market Other Major And Innovative Companies

• 31.1. Becton Dickinson and Company
• 31.2. Hologic Inc.
• 31.3. Aurobindo Pharma Limited
• 31.4. Innoviva Inc.
• 31.5. Debiopharm Group
• 31.6. Achilles Vaccines S.r.l.
• 31.7. Melinta Therapeutics LLC
• 31.8. VenatoRx Pharmaceuticals Inc.
• 31.9. Evofem Biosciences Inc.
• 31.10. Recce Pharmaceuticals Ltd.
• 31.11. Therapyx Inc.
• 31.12. Entasis Therapeutics Inc.
• 31.13. Apotex Inc.
• 31.14. Alopexx Pharmaceuticals LLC
• 31.15. Summit Therapeutics Inc.

32. Global Gonorrhea Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gonorrhea Therapeutics Market

34. Recent Developments In The Gonorrhea Therapeutics Market

35. Gonorrhea Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Gonorrhea Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gonorrhea Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gonorrhea Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer